Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-26-006621
Filing Date
2026-02-09
Accepted
2026-02-09 20:54:28
Documents
1
Period of Report
2026-02-06

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1770688465.html 4  
1 FORM 4 wk-form4_1770688465.xml 4 3786
  Complete submission text file 0001628280-26-006621.txt   5537
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Issuer) CIK: 0001516551 (see all company filings)

EIN.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ARDELYX, INC. 34715 ARDENWOOD BLVD, SUITE 100 FREMONT CA 94555
Business Address
Jenkins Annalisa (Reporting) CIK: 0001639481 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-42009 | Film No.: 26613166